IDEA #5D8T1D New Type Of Gold-Bearing Probiotic Drug "Okarin-Au" For Prophylactic And Treatment Of Disbacteriosis And Especially Dangerous Infectious Diseases Such As Anthrax, Rabbit-Fever, Brucellosis Etc.

LIFE SCIENCES • BIOLOGICALMATERIALS NEW TYPE OOFF GOLD(cid:2)(cid:2)BEARING PROBIOTIC DRUG ““OKARIN(cid:2)(cid:2)AAUU”” FOR PROPHYLACTIC AND TREATMENT OOFF DISBACTERIOSIS AND ESPECIALLY DANGEROUS INFECTIOUS DISEASES SUCH AASS ANTHRAX,, RABBIT(cid:2)(cid:2)FEVER,, BRUCELLOSIS ETC Description The deterioration of the epidemic situation in Ukraine during the last years as to tuberculosis, different hepatitis forms, infectious diseases of gastrointestinal tract, as well as con(cid:2) stant threat of ecological disasters or terrorists attacks are stimulating the research directed to the creation of new gener(cid:2) ation of more effective drugs. New type of combined probiotic drug“Okarin(cid:2)Au” for prophylactic and treatment of both dis(cid:2) bacteriosis and especially dangerous infectious diseases was developed. 3 strains of Escherichia coli and one Enterococcus faecalis strain were represented in the preparation with the ratio of 1:1:1:3. Based on four bacterial strains taken from normoflora of gastrointestinal tract of people in good health as an active ingredient, the drug is also modified by gold in col(cid:2) loidal form. Our previous investigations showed that modifica(cid:2) tion of initial probiotic drug by metals in colloid form variates the properties of the microorganisms' cultures, which formed the basis of preparation, and stimulates their biological activ(cid:2) ity. “Okarin(cid:2)Au” preparation is available in the form of gelati(cid:2) nous capsules containing dried bacterial cultures bearing col(cid:2) loidal gold particles. This approach leads to deliverance of the whole preparation without any losses directly to the part of gastrointestinal tract which demands probiotic treatment. Innovative Aspect and Main Advantages Probiotic drug “Okarin(cid:2)Au” has a number of prominent advan(cid:2) tages: • Wide range of antagonistic activity to pathogenic organ(cid:2) isms causing anthrax, rabbit(cid:2)fever, salmonellosis, brucellosis etc. (according to results of clinical trials); • Selective bactericidal activity as to pathogenic microflora and simultaneous stimulation of normoflora. This feature deals with the presence of colloidal gold metals (Fig.2); • Could be used for treatment of oncological patients due to high resistance of probiotic's microbial cultures to antibiotics and chematherapeutic agents. Also this drug has the ability to increase the lysis of atypical pathological cells; • Ability to stimulate the nonspecific immunoresistance of the whole organism; • Low cost in comparison with other probiotic drugs which are available on the market today. Areas ooff Application “Okarin(cid:2)Au” can be used for prophylaxis and treatment of dis(cid:2) bacteriosis of wide etiology including healing of oncological patients in the post(cid:2)chemotherapeutical period. Stage ooff Development Laboratory prescription for production of bacteriological con(cid:2) centrated product “Okarin(cid:2)Au” has been developed. Preparation has also passed pre(cid:2)clinical and clinical tests (result of clinical trials are shown on Fig.2). The bacterial con(cid:2) centrate "Okarin(cid:2)Au" is registered in the State Committee of Standardization, Metrology and Certifying (registration N 081/018773). 120 Fig.1. The shape of gold(cid:2)bearing probiotic drug "Okarin(cid:2)Au" Fig.2. Results of the clinical testing of the bacteriological con(cid:2) centrate "Okarin(cid:2)Au": 1 (cid:2) the state of the microbiocenosis of gastrointestinal tract of children on I(cid:2)III disbacteriosis stages 2 (cid:2) treatment by primary pathogenetic therapy 3 (cid:2) tratment by the same pathogenetic therapy along with the gold(cid:2)bearing probiotic drug "Okarin(cid:2)Au" 4 (cid:2) normal state of the digestive tract: bacteria that form the normal flora of humans GIT are marked blue when the condi(cid:2) tionally pathogenic species are marked red. Contact Details Institute of Biocolloidal Chemistry of National Academy of Sciences of Ukraine Contact person: Zoya Ulberg Address: 42, Vernadskogo Av., 03142, Kyiv, Ukraine Теl: (380 44) 424 19 19 Fax: (380 44) 424 80 78 E(cid:2)mail: zulberg@bioco.kiev.ua; tgruzina@mail.ru